SEO URLwww.firestrike.ai/deals/adverum-biotechnologies-lilly-acquisition-2026-1
acquisitionAnnounced · Feb 8, 2026BiotechnologySource · CredibleArticle · Factual
Lilly acquires Adverum Biotechnologies
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
—
Target
Adverum Biotechnologies
NASDAQ: ADVM · Redwood City, California
Acquirer
Lilly
Full Acquisition
Status
Pending
Lilly agreed to acquire Adverum Biotechnologies. Reported deal value: Undisclosed. Status: Pending. Sector: Biotechnology. Target headquarters context: Redwood City, California, United States.
This page summarizes publicly available information about the transaction as of 2026-02-08. Figures and status may change as filings and press coverage update.
Foto: über boerse-global.de Pharmaceutical giant Eli Lilly and Company has moved to strengthen its gene therapy portfolio through the strategic acquisition of Adverum Biotechnologies
Deal timeline
Announced
Feb 8, 2026 · ad-hoc-news.de
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Biotechnology. Figures and status may change as sources update.
Sources: ad-hoc-news.de · Primary article · FireStrike proprietary index